Pediatric GLP-1 Medications and Nutritional Deficiencies

Study Links Pediatric GLP-1 Treatment to Nutrient Deficiencies

Nearly one in six young patients taking glucagon-like peptide-1 (GLP-1) receptor agonists developed a diagnosed nutritional deficiency during their first year of treatment. The retrospective cohort study analyzed national claims records from 2017 through 2022. Researchers identified 2,031 patients ages 10 to 17 who had no previous record of nutritional deficits before starting the drugs.

Among the cohort, 16.8% received a diagnosis for a nutritional deficiency within 12 months. The most frequent issue was vitamin D deficiency, which affected 12.4% of the youth in the study cohort.

Prescription Patterns and Vitamin Deficiencies in Young Patients

The analysis tracked prescriptions for prediabetes, type 2 diabetes, and weight management across the study period. Liraglutide was the most common prescription at 78.6% of patients. Dulaglutide represented 10.4% of prescriptions, while semaglutide made up 9.1%.

GLP-1 medications suppress appetite and slow gastric emptying to reduce calorie intake. In pediatric patients, reduced food intake can limit the intake of vitamins and minerals required during periods of rapid bone growth and physical development. The study authors highlighted vitamin D, iron, and calcium as specific nutrients that warrant attention during adolescent growth.

Nutritional Counseling Lags Behind GLP-1 Prescriptions

Most pediatric patients in the study started therapy without formal dietary guidance. Only 5% of young patients received nutritional counseling within 30 days of starting a GLP-1 prescription. Less than 25% received dietary counseling within six months.

The researchers noted that relying on reactive testing leaves young patients exposed to unrecognized deficits during development. Bone mineralization during puberty relies on adequate calcium and vitamin D intake. When food volume drops quickly, micro-nutrient intake often falls alongside total energy intake.

Study Design and Observational Limits

The study used retrospective administrative claims data rather than randomized prospective clinical trial data. Claims data rely on diagnostic codes entered by clinicians during billing. As a result, the figures reflect only diagnosed conditions, leaving mild or subclinical deficiencies unrecorded.

The data also reflect prescribing habits from 2017 through 2022, when liraglutide dominated pediatric prescriptions. Semaglutide now accounts for a larger share of pediatric prescriptions than it did during that window. Prospective studies measuring direct blood biomarkers are still needed to confirm if newer formulations show similar deficiency rates.

Monitoring Pediatric Metabolic Therapy

Clinical teams evaluating GLP-1 medications and nutritional deficiencies in children can integrate baseline blood tests and regular dietary evaluations into standard care. Families considering these medications can ask their clinician to schedule baseline nutrient screenings and follow-up lab panels.